Learn about the latest trends and activities through our blog posts.
Back in April 2019 we published an article through Specialty Pharmacy Times titled “Don’t Ignore the Steady Drumbeat of Drug Importation?” Click here to read the article
However; we have been noticing lately that there is a lot more chatter on importation, especially from the Administration.
Read MoreOur recently recorded webinar with WellSky is now available.
Read MoreWe have a new webinar on December 4, 2019 via the American College of Apothecaries (ACA) on CBD.
Read MoreWe have a new article in the American College of Apothecaries (ACA) titled “What’s Next for DIR Policy?”
Read MoreRon Lanton III, Esq. of Lanton Law discusses with Specialty Pharmacy Times the specialty pharmacist's role in educating patients about biosimilars and biologics
Read MoreWith the release of the Administration’s American Patient’s First Blueprint in May 2018, price transparency was shown to be a centerpiece of the Administration’s governing agenda. Last week, the Administration released two rules, each at different points of the rulemaking process.
Read MoreCongresswoman Amy Spanberger (D-VA) has sponsored H.R. 2115 titled “Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act.” This is important for healthcare stakeholders, as this proposed legislation requires greater transparency for discounts provided by manufacturers. This bill also proposes to include real-time benefit information as part of a prescription drug plan’s electronic prescription program under Medicare.
Read MoreRon Lanton III, Esq., discusses the specialty pharmacist's role in educating patients about biosimilars and biologics.
Read MoreCheck out Ron Lanton’s interview with Specialty Pharmacy Times on “The Challenges to Launching Biosimilars” https://www.pharmacytimes.com/news/challenges-to-launching-biosimilars
Read MoreAt this point in the legislative calendar, it is time to take a look at what may have a likely shot at passing Congress before the 2020 election season gets underway. With the contentious debate on drug pricing that has occurred during the last several months, insulin pricing is still garnering plenty of attention.
Read MoreWatch Ron Lanton give Specialty Pharmacy Times his insight on the Prescription Drug Price Relief Act.
Read More
